
Sun Pharma and Israel-based Moebius Medical Limited have presented data at EULAR 2024 demonstrating the long-lasting pain relief achieved in knee osteoarthritis patients with the MM-II injection. Results from the randomized, controlled phase 2b clinical trial (NCT04506463) showed significant pain relief lasting 26 weeks post-injection. The MM-II injection, a novel non-opioid suspension of multilamellar liposomes, has shown promise for durable pain relief. Sun Pharma and Moebius Medical plan to initiate a phase 3 clinical program and seek a CE Mark in the EU.
Like
Save
Share